Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis
暂无分享,去创建一个
A. Traboulsee | L. Kappos | G. Comi | H.-P. Hartung | G. Comi | D. Arnold | X. Montalban | L. Kappos | A. Bar-Or | A. Traboulsee | P. Fontoura | G. Comi | F. Lublin | J. Wolinsky | H. Garren | B. Hemmer | S. Hauser | G. Giovannoni | K. Selmaj | G. Klingelschmitt | D. Masterman | S. Belachew | K. Rammohan | H. Hartung | D. L. Arnold | N. Mairon | P. Chin | X. Montalban | B. Hemmer | S. L. Hauser | A. Bar-Or | J. S. Wolinsky | G. Giovannoni | F. Lublin | K. W. Rammohan | K. Selmaj | G. Klingelschmitt | D. Masterman | P. Fontoura | S. Belachew | P. Chin | N. Mairon | H. Garren | Ludwig Kappos | Hans-Peter Hartung | Jerry S. Wolinsky | Shibeshih Belachew | Hans‐Peter Hartung | Fred Lublin | Krzysztof Selmaj | Gaelle Klingelschmitt | Hideki Garren
[1] Bernhard Hemmer,et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis , 2017, The New England journal of medicine.
[2] Alyssa H. Zhu,et al. Long‐term evolution of multiple sclerosis disability in the treatment era , 2016, Annals of neurology.
[3] H. Hartung,et al. Disease-modifying therapies and infectious risks in multiple sclerosis , 2016, Nature Reviews Neurology.
[4] P. Sørensen,et al. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects , 2016, Therapeutic advances in neurological disorders.
[5] A. Bar-Or,et al. Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy , 2015, Science Translational Medicine.
[6] D. Margolin,et al. Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis (CARE-MS) Program. , 2015, International journal of MS care.
[7] H. Weiner,et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. , 2015, JAMA neurology.
[8] S. Hauser. The Charcot Lecture | Beating MS: A story of B cells, with twists and turns , 2015, Multiple sclerosis.
[9] M. Sirota,et al. Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis , 2014, Science Translational Medicine.
[10] Steven H. Kleinstein,et al. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes , 2014, Science Translational Medicine.
[11] S. Hauser,et al. Multiple sclerosis: Prospects and promise , 2013, Annals of neurology.
[12] C. Klein,et al. Response to: Monoclonal antibodies targeting CD20 , 2013, mAbs.
[13] Martin S. Weber,et al. Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges , 2013, Therapeutic advances in neurological disorders.
[14] C. Klein,et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties , 2013, mAbs.
[15] T. Ineke,et al. A single dose of rituximab does not deplete B cells in secondary lymphoid organs, but alters phenotype and function , 2013 .
[16] D. Cox,et al. B cell exchange across the blood-brain barrier in multiple sclerosis. , 2012, The Journal of clinical investigation.
[17] Jeffrey A. Cohen,et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial , 2012, The Lancet.
[18] F. Zhu,et al. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. , 2012, Brain : a journal of neurology.
[19] Anthony Traboulsee,et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.
[20] F. Barkhof,et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial , 2011, The Lancet.
[21] R. Reynolds,et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. , 2011, Brain : a journal of neurology.
[22] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[23] Ludwig Kappos,et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring , 2007, The Lancet Neurology.
[24] M. Genovese,et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. , 2008, Arthritis and rheumatism.
[25] D. Arnold,et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.
[26] A. Bar-Or,et al. The Immunology of Multiple Sclerosis , 2008, Seminars in neurology.
[27] Thomas F. Tedder,et al. Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice1 , 2008, The Journal of Immunology.
[28] A. al‐Sabbagh,et al. Neutralizing antibodies in MS therapy: reviewing the Rebif experience , 2007 .
[29] M. Trojano,et al. New natural history of interferon‐β–treated relapsing multiple sclerosis , 2007 .
[30] M. Trojano,et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. , 2007, Annals of neurology.
[31] A. Chan,et al. B cell immunobiology in disease: evolving concepts from the clinic. , 2006, Annual review of immunology.
[32] H. Storm,et al. Cancer risk among patients with multiple sclerosis: A population‐based register study , 2006, International journal of cancer.
[33] Wolfgang Brück,et al. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage , 2005, Journal of Neurology.
[34] B. Serafini,et al. Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis , 2004, Brain pathology.
[35] Stephen M. Smith,et al. Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.
[36] J. Fischer,et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. , 2001, Archives of neurology.
[37] ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. , 2001, Journal of postgraduate medicine.
[38] S. Hauser,et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis , 1999, Nature Medicine.
[39] H. Lassmann,et al. Multiple sclerosis: In situ evidence for antibody‐ and complement‐mediated demyelination , 1998, Annals of neurology.
[40] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.